Clinical importance of DNA repair inhibitors in cancer therapy

被引：10

作者：

Hosoya N. ^{[1
]}

Miyagawa K. ^{[1
,2
]}

机构：

[1] Laboratory of Molecular Radiology, Graduate School of Medicine, University of Tokyo, Tokyo

[2] Laboratory of Molecular Radiology, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo 113-0033

来源：

memo - Magazine of European Medical Oncology | 2009年 / 2卷 / 1期

关键词：

BRCA-defective tumours; Cancer therapy; DNA repair inhibitors; PARP inhibitors; Targeted therapy;

D O I：

10.1007/s12254-008-0081-7

中图分类号：

学科分类号：

摘要：

The efficacy of cancer chemotherapy and radiotherapy relies on generation of DNA damage. Since intrinsic DNA repair pathways enable cancer cells to survive by repairing these damaged lesions, inactivation of DNA repair coupled with chemotherapy and radiotherapy has a potential to enhance the effect of these therapies. Small molecule compounds that inhibit specific DNA repair proteins have been developed, and early clinical trials are ongoing. While DNA repair inhibitors have been tried mostly as a part of combination therapies with cytotoxic agents, recent reports highlighted a new concept in cancer therapy where DNA repair inhibitors could be used as single agents to selectively kill cancer cells. This concept is based on the findings that cancer cells are frequently defective in particular DNA repair pathway(s) and the presumption that inhibition of the compensatory repair pathway(s) in such cells might be useful to kill them. For example, poly(ADP-ribose) polymerase (PARP) plays a critical role in DNA base-excision repair, and inactivation of this protein increases the number of single-strand breaks, leading to double-strand breaks that require to be repaired by homologous recombination (HR) mediated by BRCA1 and BRCA2. Recently, BRCA1- or BRCA2-defective tumour cells were shown to be sensitive to PARP inhibitors alone. This treatment may be tumour-specific because only the BRCA1-/- or BRCA2-/- tumours in the BRCA1 or BRCA2 patients are completely defective in HR repair. The following short review aims at summarizing the basic mechanisms of DNA repair and the therapeutic options using DNA repair inhibitors in cancer therapy. © 2009 Springer-Verlag.

引用

页码：9 / 14

页数：5

共 36 条

[31]

Hickson I., Zhao Y., Richardson C.J., Green S.J., Martin N.M.B., Orr A.I., Reaper P.M., Jackson S.P., Curtin N.J., Smith G.C.M., Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM, Cancer Research, 64, 24, pp. 9152-9159, (2004)

[32]

Farmer H., McCabe H., Lord C.J., Tutt A.H.J., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M.B., Jackson S.P., Smith G.C.M., Ashworth A., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, 434, 7035, pp. 917-921, (2005)

[33]

Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T., Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, 434, 7035, pp. 913-917, (2005)

[34]

Sakai W., Swisher E.M., Karlan B.Y., Agarwal M.K., Higgins J., Friedman C., Villegas E., Jacquemont C., Farrugia D.J., Couch F.J., Urban N., Taniguchi T., Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers, Nature, 451, 7182, pp. 1116-1120, (2008)

[35]

Edwards S.L., Brough R., Lord C.J., Natrajan R., Vatcheva R., Levine D.A., Boyd J., Reis-Filho J.S., Ashworth A., Resistance to therapy caused by intragenic deletion in BRCA2, Nature, 451, 7182, pp. 1111-1115, (2008)

[36]

Swisher E.M., Sakai W., Karlan B.Y., Wurz K., Urban N., Taniguchi T., Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance, Cancer Research, 68, 8, pp. 2581-2586, (2008)

← 1 2 3 4 →